STOCK TITAN

Know Labs Announces Expanded Technology Leadership in its Executive Team

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Know Labs, Inc. (NYSE American: KNW), a developer of non-invasive diagnostics technology, has announced two key additions to its executive leadership team. John Cronin joins as Interim Chief Technology Officer, bringing extensive experience in intellectual property strategy and patent development. Dominic Klyve, Ph.D., becomes Chief Science Officer, tasked with leading the research and development team in building the first non-invasive glucose monitor.

These appointments aim to accelerate platform development and secure multiple strategic partnerships. Cronin, previously a board member and strategic advisor, will oversee product development and technology strategy. Klyve, a former lead data scientist at Know Labs, brings significant research experience and has authored several studies for the company.

The expanded leadership team is expected to drive technology development and assist in bringing Know Labs' platform to market through strategic relationships with global leaders in med tech, pharma, and consumer markets.

Know Labs, Inc. (NYSE American: KNW), un sviluppatore di tecnologie diagnostiche non invasive, ha annunciato due importanti aggiunte al suo team di leadership esecutiva. John Cronin entra come Chief Technology Officer ad interim, portando con sé una vasta esperienza nella strategia della proprietà intellettuale e nello sviluppo dei brevetti. Dominic Klyve, Ph.D., diventa Chief Science Officer, incaricato di guidare il team di ricerca e sviluppo per la costruzione del primo monitor per la glicemia non invasivo.

Queste nomine mirano a accelerare lo sviluppo della piattaforma e garantire molteplici partnership strategiche. Cronin, ex membro del consiglio e consulente strategico, supervisionerà lo sviluppo del prodotto e la strategia tecnologica. Klyve, ex principale scienziato dei dati di Know Labs, porta con sé una significativa esperienza di ricerca e ha scritto diversi studi per l'azienda.

Il team di leadership ampliato dovrebbe promuovere lo sviluppo tecnologico e contribuire a portare la piattaforma di Know Labs sul mercato attraverso relazioni strategiche con leader globali nel settore della tecnologia medica, farmaceutica e dei consumatori.

Know Labs, Inc. (NYSE American: KNW), un desarrollador de tecnología de diagnóstico no invasivo, ha anunciado dos importantes adiciones a su equipo de liderazgo ejecutivo. John Cronin se une como Director de Tecnología Interino, aportando una amplia experiencia en estrategia de propiedad intelectual y desarrollo de patentes. Dominic Klyve, Ph.D., se convierte en Director Científico, encargado de liderar el equipo de investigación y desarrollo en la construcción del primer monitor de glucosa no invasivo.

Estas incorporaciones tienen como objetivo acelerar el desarrollo de la plataforma y asegurar múltiples asociaciones estratégicas. Cronin, anteriormente miembro de la junta y asesor estratégico, supervisará el desarrollo de productos y la estrategia tecnológica. Klyve, ex principal científico de datos de Know Labs, aporta una significativa experiencia en investigación y ha escrito varios estudios para la empresa.

Se espera que el equipo de liderazgo ampliado impulse el desarrollo tecnológico y ayude a llevar la plataforma de Know Labs al mercado a través de relaciones estratégicas con líderes globales en tecnología médica, farmacéutica y mercados de consumo.

Know Labs, Inc. (NYSE American: KNW), 비침습 진단 기술의 개발 업체가 임원 리더십 팀에 두 가지 주요 추가 인사를 발표했습니다. John Cronin이 임시 최고 기술 책임자로 합류하여 지적 재산 전략 및 특허 개발에 대한 풍부한 경험을 제공합니다. Dominic Klyve, Ph.D.는 최고 과학 책임자가 되어 비침습 혈당 모니터 개발을 위한 연구 및 개발 팀을 이끌게 됩니다.

이러한 임명은 플랫폼 개발을 가속화하고 여러 전략적 파트너십을 확보하는 것을 목표로 합니다. Cronin은 이전에 이사 및 전략 고문으로 활동하였으며, 제품 개발 및 기술 전략을 감독합니다. Klyve는 Know Labs의 이전 선임 데이터 과학자로서 상당한 연구 경험을 가지고 있으며, 회사의 여러 연구를 저술하였습니다.

확대된 리더십 팀은 기술 개발을 추진하고 Know Labs의 플랫폼이 의료 기술, 제약 및 소비자 시장의 글로벌 리더와의 전략적 관계를 통해 시장에 출시되는 것을 지원할 것으로 기대됩니다.

Know Labs, Inc. (NYSE American: KNW), un développeur de technologies de diagnostic non invasives, a annoncé deux ajouts clés à son équipe de direction. John Cronin rejoint en tant que directeur technique par intérim, apportant une vaste expérience en stratégie de propriété intellectuelle et en développement de brevets. Dominic Klyve, Ph.D., devient directeur scientifique, chargé de mener l'équipe de recherche et développement dans la construction du premier moniteur de glucose non invasif.

Ces nominations visent à accélérer le développement de la plateforme et sécuriser plusieurs partenariats stratégiques. Cronin, ancien membre du conseil d'administration et conseiller stratégique, supervisera le développement des produits et la stratégie technologique. Klyve, ancien scientifique des données principal chez Know Labs, apporte une expérience de recherche significative et a rédigé plusieurs études pour l'entreprise.

Le comité de direction élargi devrait favoriser le développement technologique et aider à amener la plateforme Know Labs sur le marché à travers des relations stratégiques avec des leaders mondiaux dans les secteurs de la technologie médicale, pharmaceutique et des consommateurs.

Know Labs, Inc. (NYSE American: KNW), ein Entwickler von nicht-invasiven Diagnosetechnologien, hat zwei wichtige Ergänzungen in seinem Führungsteam angekündigt. John Cronin wird Interims-Chief Technology Officer und bringt umfassende Erfahrung in den Bereichen Strategie zum geistigen Eigentum und Patententwicklung mit. Dominic Klyve, Ph.D., wird Chief Science Officer und ist damit beauftragt, das Forschungs- und Entwicklungsteam beim Aufbau des ersten nicht-invasiven Glukosemonitors zu leiten.

Diese Ernennungen zielen darauf ab, die Plattformentwicklung zu beschleunigen und mehrere strategische Partnerschaften zu sichern. Cronin, der zuvor Vorstandmitglied und strategischer Berater war, wird das Produktentwicklungs- und Technologiestrategieteam leiten. Klyve, ehemaliger leitender Datenwissenschaftler bei Know Labs, bringt bedeutende Forschungserfahrung mit und hat mehrere Studien für das Unternehmen verfasst.

Das erweiterte Führungsteam wird voraussichtlich die Technologieentwicklung vorantreiben und dabei helfen, die Plattform von Know Labs über strategische Partnerschaften mit globalen Marktführern in den Bereichen Medizintechnik, Pharma und Konsumgüter auf den Markt zu bringen.

Positive
  • Appointment of experienced executives to key leadership positions
  • Focus on accelerating platform development and securing strategic partnerships
  • Expansion of intellectual property and technology strategy capabilities
  • Strengthening of research and development team for non-invasive glucose monitoring
Negative
  • None.

Acceleration of Platform Development to Secure Multiple Strategic Partnerships

SEATTLE--(BUSINESS WIRE)-- Know Labs, Inc. (NYSE American: KNW), a leading developer of non-invasive diagnostics technology, announced today two additions to its executive leadership team. The new executives are John Cronin and Dominic Klyve, Ph.D. They are tasked with both furthering the development of the Company’s non-invasive diagnostic technology platform and building relationships with potential strategic partners.

“John and Dominic bring extensive technology leadership and research experience to the Know Labs team,” said Ron Erickson, CEO. “In their new roles they provide intellectual leadership to both drive our technology development and real-world business acumen to assist in bringing our platform to market through strategic relationships with global leaders in the med tech, pharma and consumer marketplace.”

John Cronin joins the day-to-day team as Interim Chief Technology Officer. Previously, Cronin was elected as a member of the Company’s Board of Directors. He has been a strategic advisor and consultant to Know Labs, supporting the Company’s expanding patent portfolio and securing its global leadership as the top patent holder in the non-invasive blood glucose monitoring category. Cronin will oversee the Company’s product development and technology strategy and help the Know Labs team develop test protocols to address research and development questions. In addition, Cronin spearheads the Know Labs “skunkworks” activities which explores new applications for the Company’s platform technology, an example of which is the recently announced automobile steering wheel application of our sensor platform. Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin began his career at IBM where he was the sole inventor of breakthrough chip design technology and later, he became IBM’s top inventor. He went on to create the IBM Patent Factory, growing IBM’s patent portfolio from ninth to first in the world catapulting IBM’s IP licensing from $30 million to over $2 billion a year. Today, Mr. Cronin has approximately 1800 patents and applications worldwide.

Dominic Klyve, Ph.D., a long-time consultant and previous employee of the Company, joins as Chief Science Officer. Dr. Klyve previously served as lead data scientist at Know Labs. As Chief Science Officer, he will be responsible for leading the research and development team in its efforts to build the first non-invasive glucose monitor. Klyve has been an author on several studies published by Know Labs, including its most recent peer-reviewed study published in IEEE Sensors Journal detailing historical developments and limitations with RF-based sensing technologies, and the distinctiveness of Know Labs’ sensor architecture and trade-secret prediction machine learning algorithm. Klyve is the author of more than 80 peer-reviewed publications in several fields of science and mathematics and has served as Principal Investigator on grants from the National Science Foundation (among others) worth over $1.5 million. He holds a professorship at Central Washington University, where he is currently on sabbatical, and is a former Editor of the College Mathematics Journal.

For more information on Know Labs, visit www.knowlabs.co.

About Know Labs, Inc.

Know Labs, Inc. is a public company whose shares trade on the NYSE American Exchange under the stock symbol “KNW.” The Company’s platform technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. The technology is designed to able to integrate into a variety of wearable, mobile or bench-top form factors. The Company believes that this patented and patent-pending technology makes it possible to effectively identify and monitor analytes that could only previously be performed by invasive and/or expensive and time-consuming lab-based tests. The Company’s first expected application of the technology will be in a product marketed as a non-invasive glucose monitor. The device is designed to provide the user with accessible and affordable real-time information on blood glucose levels. This product will require U.S. Food and Drug Administration clearance prior to its introduction to the market.

Safe Harbor Statement

This release contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Know Labs, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy; and (iv) performance of products. You can identify these statements by the use of the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Know Labs, Inc.’s ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. These risks and uncertainties also include such additional risk factors as are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended September 30, 2023, Forms 10-Q and 8-K, and in other filings we make with the Securities and Exchange Commission from time to time. These documents are available on the SEC Filings section of the Investor Relations section of our website at www.knowlabs.co. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

Know Labs, Inc.

Jordyn Hujar

jordyn@knowlabs.co

Ph. (206) 629-6414

Source: Know Labs, Inc.

FAQ

What new executive appointments did Know Labs (KNW) announce?

Know Labs (KNW) announced the appointment of John Cronin as Interim Chief Technology Officer and Dominic Klyve, Ph.D., as Chief Science Officer.

What is the main goal of Know Labs' (KNW) new executive appointments?

The main goal is to accelerate platform development and secure multiple strategic partnerships with global leaders in med tech, pharma, and consumer markets.

What is John Cronin's background and role at Know Labs (KNW)?

John Cronin is the founder and CEO of ipCapital Group, Inc. At Know Labs (KNW), he will oversee product development, technology strategy, and lead 'skunkworks' activities exploring new applications for the company's platform technology.

What is Dr. Dominic Klyve's role at Know Labs (KNW)?

Dr. Dominic Klyve is the new Chief Science Officer at Know Labs (KNW), responsible for leading the research and development team in building the first non-invasive glucose monitor.

Know Labs, Inc.

NYSE:KNW

KNW Rankings

KNW Latest News

KNW Stock Data

27.46M
79.96M
26.05%
4.83%
1.2%
Scientific & Technical Instruments
Measuring & Controlling Devices, Nec
Link
United States of America
SEATTLE